EVALI versus MIS-C, one
more overlapping diagnosis to consider
Diego A Cruz-Vidal, MD1, Eric S Mull,
DO2, Jeanette Taveras, DO1, Richard
Shell, MD2, Garrett W. Hunt, MD1,
Brain Fowler, BA1, Rebecca Wallihan,
MD1, Guliz Erdem, MD1
Affiliations : 1Division of Infectious
Diseases, Nationwide Children’s Hospital, Columbus, Ohio,2Division of Pulmonary Medicine, Nationwide Children’s
Hospital, Columbus, Ohio
Address correspondence to : Guliz Erdem, Division of Infectious
Diseases, Nationwide Children’s Hospital, 700 Children’s drive,
Columbus, OH, 43205, [Guliz.Erdem@nationwidechildrens.org],
614-722-8925
Short title: EVALI versus MIS-C
Conflict of Interest Disclosures: The authors have no conflicts
of interest relevant to this article to disclose
Funding/Support : No funding was secured for this study.
Abbreviations :
MIS-C: multisystem inflammatory syndrome in children; EVALI:
E-cigarette, or vaping, product use-associated lung injury; COVID-19:
Coronavirus disease 2019; CDC: Centers for Disease Prevention and
Control; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein;
PCT: Procalcitonin; LDH: Lactate Dehydrogenase; NP: Nasopharyngeal;
FRVP: FilmArray® respiratory panel; THC: tetrahydrocannabinol; CT:
Computerized tomography; BAL: Bronchoalveolar Lavage
Summary :
We describe 6 teenagers with suspected MIS-C in which EVALI was the
final diagnosis; we emphasis the importance of including EVALI as a
differential diagnosis.